CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 86 enrolled
Drug / intervention
Mirtazapine +1 moredrug
Likely dose
Mirtazapine 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04748523
NCT04748523N/ACompleted

Effect of Mirtazapine Versus Placebo on Appetite, Nutritional Status and Quality of Life in Non-small Cell Lung cáncer Patients With Anorexia; Randomized Double-blind Clinical Trial.

Instituto Nacional de Cancerologia de Mexico·interventional·Posted Feb 10, 2021·Updated Apr 27, 2023

In Brief

A clinical study evaluating Mirtazapine and Placebo Oral Tablet for Anorexia and Non-small Cell Lung Cancer. Completed, enrolled 86 participants across 1 site.

Detailed Summary

The realization of this project will generate an important advance in knowledge regarding one of the most important comorbidities in cancer patients: malnutrition. Currently, comprehensive treatments of cancer patients recognize the importance of the assessment of nutritional status, and the impact it has on the prognosis, quality of life and toxicity generated by cancer treatment. Due to this, it is imperative to offer diagnostic tools that identify patients in a timely manner and, in addition to this, offer therapeutic strategies for the improvement of nutritional status, in an adjuvant manner to their oncological treatment. It is widely recognized that the cachexia-anorexia syndrome (CACS) is present in 30 to 80% of cases in cancer patients and this proportion increases as the disease progresses, with weight loss being a powerful predictor of shorter survival. Unfortunately, current therapies available to treat anorexia and / or cancer-associated cachexia offer only partial results, mainly because the intervention is late and the development of an earlier and more effective intervention is still sought. Mirtazapine has recently gained attention not only because of its antidepressant effect, but also because of its potential benefit in patients with anorexia and weight loss, recently reported in a phase II study. Therefore, it is important to continue its evaluation through a randomized, double-blind clinical trial in which the effect of mirtazapine is compared and it is determined if it is superior compared to placebo to increase appetite in patients with NSCLC who present with anorexia. This type of strategy is a relevant therapeutic option in those patients in whom nutritional counseling by itself is not sufficient to counteract the damage caused by anorexia and to cope with or prevent the development of cachexia.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesMexico
Collaborators--

Timeline

N/ACompletedFinished
20192020202120222023202420252026
First PostedFeb 10, 2021
Enrollment StartAug 29, 2018
Primary CompletionJul 29, 2022
Study CompletionOct 29, 2022
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 5.4 years ago

Interventions

Mirtazapinedrug

arm to receive 15 to 30 mg of Mirtazapine for a period of 8 weeks.

Placebo Oral Tabletdrug

arm to receive 15 to 30 mg of Placebo for a period of 8 weeks.